| Jul 29 |
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks
|
| Jul 29 |
FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold
|
| Jul 29 |
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
|
| Jul 26 |
vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink
|
| Jul 26 |
FDA places clinical hold on vTv's cadisegliatin clinical program
|
| Jul 26 |
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
|
| Jun 24 |
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
|
| May 28 |
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
|
| May 27 |
Shareholders in vTv Therapeutics (NASDAQ:VTVT) are in the red if they invested three years ago
|
